TechBio Startup Cure51 Selects 10x Genomics Visium HD For New Drug Discovery Initiative; Cure51 Plans To Analyze More Than 1,000 Tumor Samples From Exceptional Cancer Survivors
TechBio Startup Cure51 Selects 10x Genomics Visium HD For New Drug Discovery Initiative; Cure51 Plans To Analyze More Than 1,000 Tumor Samples From Exceptional Cancer Survivors
Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors
Cure51計劃分析來自傑出癌症倖存者的1000多個腫瘤樣本
PARIS and PLEASANTON, Calif., Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer survivors, whose survival mechanisms could hold the key to new therapeutic approaches.
Working alongside more than 50 medical institutions, Cure51 intends to collect and analyze tumor tissues from over 1,000 exceptional cancer survivors across 40 countries in the next 18 months. By using Visium HD from 10x Genomics, Cure51 aims to uncover new insights into long-term cancer survival mechanisms and build the first proprietary multi-omics database of exceptional cancer survivors.
法國TechBio初創企業Cure51和10x genomics,Inc.（納斯達克：TXG），一家領先的單細胞和空間生物學公司，今天宣佈Cure51將部署10x genomics的Visium HD，作爲其開創性工作的一部分，旨在了解傑出癌症倖存者獨特的生物學特徵，其存活機制可能是新治療手段的關鍵。
與50多家醫療機構合作，Cure51打算在未來18個月內收集和分析來自40個國家超過1,000名優秀癌症倖存者的腫瘤組織。通過使用10x genomics的Visium HD，Cure51旨在揭示對長期癌症存活機制的新見解，並建立首個獨有的多組學數據庫，供大規模癌症倖存者使用。
譯文內容由第三人軟體翻譯。
